 | This article may rely excessively on sources too closely associated with the subject , potentially preventing the article from being verifiable and neutral.(August 2024) |
N. Anthony Coles is an American physician, biotechnology entrepreneur, and pharmaceutical leader. Since 2018, Coles has served as chair of the board of directors for Cerevel Therapeutics.
N. Anthony Coles was born on May 17, 1960, in Roanoke, Virginia, to Neavelle Anthony Coles, an accountant and minister, and Leona Rogers Coles, an office manager for a local telephone company. [1] Coles graduated from DuVal High School in Lanham, Maryland. [2]
Coles earned his bachelor's degree at Johns Hopkins University, and his medical degree from Duke University. His medical school alma mater awarded him the Duke School of Medicine 2024 Transformational Leadership Award. [3]
Coles also earned a master's degree in public health from Harvard University, completed his cardiology and internal medicine training at Massachusetts General Hospital, and a research fellowship at Harvard Medical School. [4]
In 2021, Coles was elected to the American Academy of Arts & Sciences. [5]
Since 2018, Coles has served as chair of the board of directors for Cerevel Therapeutics, a company focused on neurological disease treatment. From September 2019 to June 2023, Coles was Cerevel's chief executive officer of Cerevel Therapeutics Holdings, Inc., the parent entity of Cerevel Therapeutics, Inc. [6] [7] In 2020, Coles led Cerevel's effort to raise $445 million for brain drugs, the third largest biotech public listing at that time (after Legend Biotech and Moderna). [8] In May 2023, Coles resigned from his position as CEO, yet retained his role as board chairman of Cerevel. [9]
Coles served as president and chief executive officer, and a member of Onyx Pharmaceuticals board of directors, from 2008 to 2012, and as president, chief executive officer, and chairman of the board from 2012 to 2013. [10] [11] Coles orchestrated the sale of Onyx to Amgen ($AMGN) for $10.4 billion. [12]
Coles has served as chair and CEO of TRATE Enterprises, a privately held real estate management and ventures company, since 2013. [13]
In October 2014, Coles co-founded (with researcher Susan Lindquist) and served as chair and CEO of Yumanity Therapeutics, a biopharmaceutical company specializing in Alzheimer's and Parkinson's diseases. [10] [12] [1]
In 2005, Coles joined NPS Pharmaceuticals, Inc. as company COO and president, and in 2006, was named chief executive officer. [14]
In addition, Coles held various roles at Bristol-Myers Squibb (senior vice president of strategy and policy and senior vice president of marketing and medical affairs, neuroscience/infectious diseases/dermatology where he was responsible for a $1.8 billion portfolio); Merck & Co, Inc. (oversaw the marketing of ACE inhibitors to cardiologists), and Vertex Pharmaceuticals, Inc.(senior vice president of commercial operations-pharmaceutical products). [2] [14]
He is a former director of CRISPR Therapeutics AG; [15] Laboratory Corporation of America Holdings; Campus Crest Communities, Inc.; and McKesson Corporation; and currently serves on the board of directors of Regeneron Pharmaceuticals, Inc. [13]
Coles is the co-founder and co-chairman of the Black Economic Alliance. [16] He is a Trustee Emeriti of The Johns Hopkins University Board of Trustees; [17] a former member of the Harvard Medical School Advisory Board; [18] council chair for the National Museum of African American History and Culture; a member of the Board of Trustees of the Metropolitan Museum of Art; member of the board of directors on the Council on Foreign Relations; and member of the U.S. Olympic and Paralympic Foundation. [10] [5]
Coles and his wife, Robyn Coles, [19] have three sons. Their oldest son was diagnosed with non-Hodgkin's lymphoma, at the age of 12, and underwent a bone marrow transplant protocol at Memorial Sloan Kettering. [11] [20]
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Ernest Mario is an American pharmaceutical industry executive and the recipient of the 2007 Remington Honor Medal awarded by the American Pharmacists Association.
CHI-California Healthcare Institute is a private, non-profit public policy research and advocacy organization, representing more than 250 universities, academic research centers, biotechnology, and medical device companies. Founded in 1993, and based in La Jolla, California, CHI has offices in Washington, D.C., and Sacramento, California. CHI publishes an annual California Biomedical Industry report, providing data on the scope and scale of academic and commercial life sciences research and development within the state. In 2008, the industry employed more than 270,000 Californians and produced revenues in excess of $75 billion.
Marc Trevor Tessier-Lavigne is a Canadian-American neuroscientist who was the eleventh president of Stanford University.
Phillip Frost is an American entrepreneur.
Onyx Pharmaceuticals Inc. has been a biopharmaceutical company headquartered in South San Francisco, California. The company developed and marketed medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. McCormick served as the chief scientific officer until 1998, while Kinsella was the firm's chairman. In 2009, the company acquired Proteolix, Inc., a private biotechnology company, for $276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx president and chief executive officer (CEO) N. Anthony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, at the end of August 2013, Amgen announced it was acquiring Onyx in an agreed $10.4 billion deal.
Jeremy Levin is a South African-born biopharmaceutical executive and medical doctor. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry and, in 2023, was awarded the Lifetime Achievement Award at the 19th Annual Scrip Awards in London.
Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.
Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.
David Meek is an American businessman. He held various global executive positions in major pharmaceutical and biotechnology companies.
Steven M. Paul is an American neuroscientist and pharmaceutical executive. Paul was the former CEO, president, and chairman of Karuna Therapeutics.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.
The Black Economic Alliance (BEA) is a United States nonprofit, nonpartisan organization of Black business leaders and allies established in 2018. While not formally aligned with either the Democratic or Republican political party, its initial slate of endorsements were for Democratic candidates.
William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He was a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Iambic Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.
Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.
Cerevel Therapeutics Holdings, Inc. is an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses.